SCRM Bio, LLC, a subsidiary of Bioramics, is advancing Agerea™, an emerging biotechnology designed to control how therapeutic cells behave at the moment of delivery. Rather than focusing on how cells are preserved before use, Agerea addresses what happens after cells are introduced into tissue, where therapeutic value is ultimately determined.

Where Cell Therapy Breaks Down

Across regenerative medicine and cell therapy, the primary limitation is not cell quality at preparation. It is the rapid loss of viable cells immediately following injection.
 

Cells tend to aggregate at the delivery site, exceeding oxygen diffusion limits and reducing nutrient access. This leads to significant loss of functional cells within days, meaning a large portion of the intended therapeutic dose never translates into meaningful biological impact.

A New Point of Control

Agerea is designed to directly influence this post delivery phase.
 

By modifying how cells interact during preparation and administration, it enables more uniform dispersion within tissue, reduces localized clustering, and supports a broader distribution of viable cells across the target area. The same number of delivered cells can therefore produce materially different outcomes depending on how they behave after injection.

From Passive Delivery to Controlled Performance

This approach represents a shift in how cell therapy performance is understood.
 

Delivery is no longer treated as a passive step. Agerea introduces a controllable layer within the workflow that directly impacts effective dose, spatial distribution, and overall therapeutic consistency. It does not require modification of the underlying therapy and is designed to integrate within existing preparation and delivery processes.
 

Broad Compatibility Across Cell Types

Because its mechanism is non biologic in nature, Agerea is inherently adaptable across a wide range of therapeutic applications.
 

This includes stem cell therapies, myogenic and regenerative programs, and emerging cell based treatments. The platform can enhance multiple therapies without requiring changes to the therapies themselves.

A Platform Positioned for Integration

SCRM Bio is advancing Agerea through continued preclinical validation and strategic engagement with industry partners.
 

The focus is not on creating a standalone product, but on enabling a new level of control within cell therapy workflows. This allows preserved cell quality to be translated into realized therapeutic performance at the point where outcomes are determined.

Strategic Relevance

For biopharma companies, device manufacturers, and strategic acquirers, SCRM Bio represents an opportunity to extend value beyond cell preservation and into therapeutic performance.
 

It introduces a new layer within existing workflows without requiring disruption, creating a clear path for integration and value creation across the cell therapy landscape.

SCRM Bio, LLC is currently available for acquisition by qualified strategic partners seeking to integrate this capability within existing cell therapy platforms.